These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29288534)

  • 1. An overview on Vadimezan (DMXAA): The vascular disrupting agent.
    Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Samandari-Rad S; Zarghami N
    Chem Biol Drug Des; 2018 May; 91(5):996-1006. PubMed ID: 29288534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
    Baguley BC; Siemann DW
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1413-25. PubMed ID: 20964495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
    J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.
    Buchanan CM; Shih JH; Astin JW; Rewcastle GW; Flanagan JU; Crosier PS; Shepherd PR
    Clin Sci (Lond); 2012 May; 122(10):449-57. PubMed ID: 22142330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).
    Jameson MB; Head M
    Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1315-26. PubMed ID: 21870897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Suppresses macrophage capping protein beyond STING activation.
    Xiao Z; Cui X; Liu F; Wang Y; Liu X; Zhou W; Zhang Y
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167149. PubMed ID: 38565383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Conlon J; Burdette DL; Sharma S; Bhat N; Thompson M; Jiang Z; Rathinam VA; Monks B; Jin T; Xiao TS; Vogel SN; Vance RE; Fitzgerald KA
    J Immunol; 2013 May; 190(10):5216-25. PubMed ID: 23585680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule cytokine inducers causing tumor necrosis.
    Baguley BC
    Curr Opin Investig Drugs; 2001 Jul; 2(7):967-75. PubMed ID: 11757800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASA404: update on drug development.
    Rehman F; Rustin G
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1547-51. PubMed ID: 18808313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach.
    Pan ST; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():937-68. PubMed ID: 25733813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DMXAA: an antivascular agent with multiple host responses.
    Baguley BC; Ching LM
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1503-11. PubMed ID: 12459378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
    Wang LC; Thomsen L; Sutherland R; Reddy CB; Tijono SM; Chen CJ; Angel CE; Dunbar PR; Ching LM
    Neoplasia; 2009 Aug; 11(8):793-803. PubMed ID: 19649209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA.
    Barbera M; Kettunen MI; Caputo A; Hu DE; Gobbi S; Brindle KM; Carrara M
    Int J Oncol; 2009 Jan; 34(1):273-9. PubMed ID: 19082498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
    Sun J; Wang LC; Fridlender ZG; Kapoor V; Cheng G; Ching LM; Albelda SM
    Biochem Pharmacol; 2011 Nov; 82(9):1175-85. PubMed ID: 21819972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.
    Baguley BC; McKeage MJ
    Future Oncol; 2010 Oct; 6(10):1537-43. PubMed ID: 21062153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
    Cai SX
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.